| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.2 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.2 |